New hope for kidney disease: HRS-5965 aims to slow IgA nephropathy
NCT ID NCT07582133
First seen May 14, 2026 · Last updated May 14, 2026 · Updated 1 time
Summary
This study tests the long-term safety of an experimental drug, HRS-5965, in 380 adults with primary IgA nephropathy, a kidney disease. The goal is to see if the drug can reduce protein in the urine and help preserve kidney function over time. Participants must have completed a prior HRS-5965 study. The trial is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IGA NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University First Hospital
Beijing, Beijing Municipality, 100000, China
Contact
Conditions
Explore the condition pages connected to this study.